FGF21 and Insulin resistance: Since the FGF21’s improvement of insulin resistance is largely attributed to enhanced insulin action in the liver [26–30], we suggest that the EPO’s enhancement of BAT derived-FGF21 secretion contributes to the reduction of gluconeogenesis of liver in induced obese mice on a high-fat diet.